[New developments in immunosuppressive therapy].
A highly effective immunosuppressive therapy with as few side effects as possible can only be achieved by a reliable drug monitoring. For neoral monitoring of the C2 level is essential while for tacrolimus measuring of the trough level is sufficient. Due to the different immunogenicity of the organ transplants the type and intensity of the immunosuppressive therapy should be organ-specific. Sirolimus is highly effective in combination with calcineurin antagonists in immunologically high-risk patients. In addition in case of severe side effects sirolimus can substitute for the calcineurin antagonists. Il-2 receptor antibodies are characterized by minimal side effects and have been shown to be a highly effective new therapeutic principle for immunosuppressive induction therapy.
Hopt
U T
UT
Chirurgische Universitätsklinik Freiburg, Hugstetterstrasse 55, 79106 Freiburg.
D000906:Antibodies / Q000009:adverse effects / Q000627:therapeutic use; D003175:Complement C2 / Q000378:metabolism; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D016903:Drug Monitoring; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015375:Receptors, Interleukin-2 / Q000276:immunology; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects; D014181:Transplantation Immunology / Q000187:drug effects*
D000906:Antibodies; D003175:Complement C2; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; D020123:Sirolimus; D016559:Tacrolimus